Paolo Colombo, MD
Advanced Heart Failure and Transplant Cardiology · New York, NYNPI 1336226810
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (56.9%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. Abbott accounts for 84.9% of it on its own, with 16 other manufacturers making up the rest. Reporting peaked in 2022 at $14,788 and has fallen 89.6% since, to $1,538 in 2025.
Across 280 payments — averaging $158.56 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$38K
- Roche Diagnostics International Ltd$5K
- Novartis$747
- Janssen Scientific Affairs, LLC$439
- Medtronic$288
- Abiomed$136
- plus $523 from 11 others
What the payments were for
- Speaking & faculty fees$25,25057%
- Travel & lodging$6,29314%
- Food & beverage$12,85429%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abbott | 200 | $37,715 |
| Roche Diagnostics International Ltd | 1 | $4,550 |
| Novartis | 52 | $747 |
| Janssen Scientific Affairs, LLC | 5 | $439 |
| Medtronic(2 entities) | 3 | $288 |
| Abiomed | 1 | $136 |
| Cvrx, Inc. | 1 | $116 |
| La Jolla Pharmaceutical Company | 1 | $100 |
| Boehringer Ingelheim | 4 | $67 |
| Merck | 3 | $66 |
| Daiichi Sankyo Inc. | 2 | $42 |
| Amgen | 2 | $38 |
| E.r. Squibb & Sons, L.L.C. | 1 | $23 |
| Kiniksa Pharmaceuticals, Ltd. | 1 | $21 |
| Novo Nordisk | 1 | $20 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 1 | $17 |
| Lexicon Pharmaceuticals, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- THORATEC HEARTMATE 3 LVAS IMPLANT KIT$13,880
- CARDIOMEMS$6,368
- CardioMEMS HF System$5,634
- HeartMate Touch$5,345
- HeartMate 3 Left Ventricular Assist Device$1,017
- HeartMate 3 Left Ventricular Dev$530
- MitraClip System$435
- HeartWare HVAD$242
- MitraClip$136
- Impella$136
- THORATEC HEARTMATE II, LVAS IMPLANT KIT$134
- HeartMate$125
- Barostim Neo System$116
- Cardiovascular- Research only$108
How this compares
$44,397 in reported general payments places this provider in the 85th percentile of 106 advanced heart failure and transplant cardiology providers in New York.
See all advanced heart failure and transplant cardiology providers in New York →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VyndamaxTafamidis | 11 | $238,785 |
| Everolimus | 17 | $38,881 |
| EntrestoSacubitril/Valsartan | 13 | $21,059 |
| Daptomycin | 29 | $16,609 |
| Mycophenolate Mofetil | 17 | $6,453 |
| Repatha SureclickEvolocumab | 12 | $6,305 |
| Tacrolimus | 14 | $3,874 |
| Atorvastatin Calcium | 36 | $351 |
| Metoprolol Succinate | 14 | $186 |
| Prenatal Vitamin Plus Low IronPnv,calcium 72/Iron/Folic Acid | 15 | $181 |
| Amlodipine Besylate | 21 | $97 |
| Losartan Potassium | 17 | $77 |
| Rosuvastatin Calcium | 27 | $63 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| NovartisEntresto | $747 | $21,05913 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 106 advanced heart failure and transplant cardiology providers in New York.
Other advanced heart failure and transplant cardiology in New York
- Johanna ContrerasNew York$534K
- Sean PinneyNew York$305K
- Mathew MaurerNew York$249K
- Dor LotanNew York$158K
- Nir UrielNew York$125K
- Gabriel SayerNew York$95K
- Parag GoyalNew York$87K
- Alex ReyentovichNew York$49K
- Melana YuzefpolskayaNew York$44K
- Kelly AxsomNew York$33K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.